SUPERNUS PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
About Supernus Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Supernus Pharmaceuticals, Inc. is a biopharmaceutical enterprise that develops and commercializes therapies addressing central nervous system disorders. The company's portfolio encompasses commercial treatments for attention-deficit hyperactivity disorder, Parkinson's disease motor complications, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea, alongside clinical pipeline candidates in neurology and psychiatry. Supernus distributes its pharmaceutical products predominantly to wholesalers, specialty pharmacies, and distributors, while certain injectables are also purchased directly by healthcare providers and hospitals.
The company operates within the United States using dedicated commercial sales organizations and collaborates with external pharmaceutical partners for international commercialization across regions including Europe, Canada, and parts of Asia. It relies on third-party contract manufacturers located across North America, Europe, and Asia for all active substances and finished product manufacturing. Supernus maintains its corporate headquarters and principal executive offices in Rockville, Maryland.
Summary of the business section of Supernus Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SUPERNUS PHARMACEUTICALS, INC.
- Founded
- 2005
- Headquarters
- Rockville, MD
- Address
- 9715 Key West Avenue 20850
- Phone
- (301) 838-2500
- Employees
- 778, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMGLLP, Baltimore, Maryland
Stock & identifiers
- Ticker
- SUPN
- Exchange
- Nasdaq
- IPO date
- May 2, 2012
- Shares outstanding
- 58M, Jul 28, 2026
- Public float
- $1.69B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1356576
- CUSIP
- 868459108
- ISIN
- US8684591089
- LEI
- 549300GRM36VBKISYJ58
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jack A. Khattar | President, CEO, Director | 2,216,451 |
| Jonathan Rubin | SVP, Chief Medical Officer | 14,342 |
| Padmanabh P. Bhatt | Sr. VP of IP, CSO | 19,795 |
| Frank Mottola | SVP, Chief Tech. Ops. Officer | 19,544 |
| Timothy C. Dec | Senior Vice-President & CFO | 9,129 |
| William Todd Horich | SVP, Commercial Operations | 4,832 |
| Frederick M. Hudson | Director | 60,413 |
| Georges Gemayel | Director | 36,064 |
| Carrolee Barlow | Director | 27,045 |
| Charles W. Newhall Iii | Director | 6,365,369 |
| Bethany Sensenig | Director | 4,475 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jack Khattar | $15.50M | $23.74M | $1.53M | $198 | $125 |
| FY2024 Jack Khattar | $12.64M | $9.24M | $1.59M | $144 | $93 |
| FY2023 Jack Khattar | $13.28M | $13.49M | $1.81M | $115 | $94 |
| FY2022 Jack Khattar | $10.01M | $11.06M | $1.17M | $142 | $90 |
| FY2021 Jack Khattar | $8.12M | $7.91M | $979.01K | $116 | $100 |
| FY2020 Jack Khattar | $6.67M | $6.13M | $1.20M | $106 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 778 full-time employees in the U.S.”
Corporate history
Events identified from SEC filings